Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Aberdeen, aCARD, acknowledged, Acta, Adolfssonet, aggregationin, Alexandre, Amron, andPyrin, Anexclusive, anin, answer, antibodiesin, AppTec, archiving, array, arrow, ASC, asthma, asymmetrical, Atalet, attenuation, AVP, Ayalonet, Bangalore, BBI, Belgrade, bifurcated, Bittneret, Bojana, Bojanna, bowel, Brexit, broadest, Bullichet, Caratsch, cardiovascular, caudate, CBD, CBS, CEIPI, Celgene, Center, CFS, characterizedin, Choiet, comparted, compelled, concurrently, confusion, constantly, coronal, CPP, Cummingset, Cx, cybersecurity, danger, Dempseyet, Dipl, discretionary, dual, EANM, EFMC, EMEA, en, enrollee, etiology, Eurozone, exacerbation, Exploit, fatty, fed, female, fibrillary, FLD, florbetapir, florebetapir, FluoroTau, forclude, formationin, FTLD, fusiform, gasdermin, GFAP, Gordonet, gosuranemab, gout, great, hallmark, HC, HD, hindsight, Honigberget, host, Hubei, hyperstimulated, idiopathic, immunostained, implicit, index, ineffective, inflammasome, Ing, installment, insulin, ischaemic, Japanese, JSC, Julien, Kerchneret, LAURIET, lawyer, licensegranted, lifestyle, liver, loan, Luket, Lymphoma, lysate, machinery, male, Maloneyet, Mantle, margin, McDadeet, Medtronic, Meilandtet, midbrain, MIPLM, mixture, modulation, moiety, Mol, mono, monosodium, monotherapy, MSA, MSU, Muelleret, multicenter, multinational, Myeloma, NASH, NDC, Neuraceq, neurogranin, neurologist, NeuroOrphan, Neuropath, neuropathology, NeuroToolkit, neutral, neutralize, NFL, nigra, nonalcoholic, Nucl, occipital, ofproinflammatory, OLE, orthogonalin, outbreak, overstimulated, parietal, Pennsylvania, Pfeiferet, phosphotau, PK, Polhamuset, polled, Polymer, Portmann, precautionary, productionin, proinflammatory, promotedex, proprietaryin, Province, psychiatry, putamen, Ramsdenet, Ransohoffet, renegotiate, rescue, retaliatory, retest, Revlimid, Richardson, Robinsonet, Roesleret, row, Roy, SAE, Schematic, semorinemab, sensing, Serbia, SGS, SOX, speck, spreadingin, STA, Stephenset, STM, stroke, Strydom, substantia, substudy, suspected, Symposium, Syngene, synucleinopathy, TAURIEL, testedin, transfected, traumatic, truncation, tTau, Twyman, UCB, Ultschet, underpinning, understood, undiscounted, unwanted, urate, USA, Vanegaset, vehicle, ventral, vii, vitrousing, VM, Walkeret, wider, Wuhan, XXV, Yanget, yearly, Zagotenemab
Removed:
accidental, adversarial, AEs, amino, APRI, assumption, atypical, bankruptcy, bear, Bioquality, Boston, Bundespresident, Bundesverdienstkreuz, chest, colon, combine, combining, conformationally, conveyed, correlation, cytotoxicity, Dean, decided, departure, detecting, Detlev, diagram, differentiate, Direvo, disorientation, dispositive, eighteen, Elan, enabled, enabling, Erkrath, Ernst, Evoxx, Faculty, fall, fellow, fibrillar, FINRA, fluid, forfeited, forfeiture, fundamentally, Gehrig, glaucoma, guest, halt, Heidelberg, hematoma, hereto, hip, hypertension, imbalance, infection, Isle, Klasse, Leerink, Lou, malignant, marker, melanoma, Monheim, NewLab, noted, ocular, orientation, overallotment, overdose, pain, pathogenic, pneumonia, polyclonal, polyp, positioning, potency, powerful, premotor, priced, Princeton, printing, PrioNet, Prof, professorship, proportion, Qiagen, recruit, redemption, reducedin, remained, removed, rent, replacing, reportable, revealed, Rhein, Riesner, serum, sick, stain, stimulated, stimulating, subdural, Suisse, synuclein, threatened, toxicity, twenty, unrelated, violating, volumetric, wound, yielding, Young
Filing tables
Filing exhibits
ACIU similar filings
Filing view
External links
EXHIBIT 15.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-213865) pertaining to the AC Immune SA 2013 Equity Incentive Plan, the Employee Stock Option and Share Plan of AC Immune (2005), and the Stock Option Plan – AC Immune of December 31, 2004 of AC Immune SA, |
(2) | Registration Statement (Form S-8 No. 333-216539) pertaining to the AC Immune SA 2016 Stock Option and Incentive Plan of AC Immune SA; |
(3) | Registration Statement (Form F-3 No. 333-224694) of AC Immune SA; and |
(4) | Registration Statement (Form F-3 No. 333-227016) of AC Immune SA. |
of our report dated March 20, 2018, with respect to the financial statements of AC Immune SA, included in this Annual Report (Form 20-F) for the year ended December 31, 2017.
/s/ Ernst & Young AG
Petit-Lancy, Switzerland
March 30, 2020